InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,304.72
(
0.70%
)
US TECH 100
18,318.00
(
0.95%
)
Dow Jones
39,069.59
(
0.01%
)
Brent Oil
81.97
(
0.00%
)
Bitcoin
69,130.30
(
0.87%
)
Post# of 251939
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 829
Posts 119690
Boards Moderated 16
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 179777

Thursday, 08/07/2014 8:48:15 AM

Thursday, August 07, 2014 8:48:15 AM

Post# of 251939
NVS advances ENTA’s EDP-239 into DDI study with NVS’ Alisporvir in healthy volunteers:

http://finance.yahoo.com/news/enanta-pharmaceuticals-hcv-ns5a-inhibitor-123000111.html

Following the DDI study, NVS will conduct a phase-2b trial of EDP-239 + Alisporvir in HCV patients, at which point ENTA will earn a $15M milestone payment.

All told, ENTA is eligible to receive $395M in pre-commercial milestone payments from NVS (including the above $15M) and $160M in commercial milestones.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up